Cargando…

Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4(+) CAR T Cell Efficacy

Chimeric antigen receptor (CAR) T cell efficacy against solid tumors is currently limited by several immune escape mechanisms, which may include tumor-derived extracellular vesicles. Advanced neuroblastoma is an aggressive childhood tumor without curative treatment options for most relapsed patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Solin, Toews, Karin, Schwiebert, Silke, Klaus, Anika, Winkler, Annika, Grunewald, Laura, Oevermann, Lena, Deubzer, Hedwig E., Tüns, Alicia, Jensen, Michael C., Henssen, Anton G., Eggert, Angelika, Schulte, Johannes H., Schwich, Esther, Rebmann, Vera, Schramm, Alexander, Künkele, Annette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137471/ https://www.ncbi.nlm.nih.gov/pubmed/32296437 http://dx.doi.org/10.3389/fimmu.2020.00531

Ejemplares similares

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
por: Andersch, Lena, et al.
Publicado: (2019)

A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization
por: Grunewald, Laura, et al.
Publicado: (2021)

CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus
por: Textor, Ana, et al.
Publicado: (2021)

Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis
por: Sulejmani, Ornela, et al.
Publicado: (2021)

What we learned from bench to bedside with the neuroblastoma targeting CD171-specific CAR
por: Künkele, A, et al.
Publicado: (2015)

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
por: Gottlieb, Aline, et al.
Publicado: (2017)

Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2020)

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study
por: Launspach, Michael, et al.
Publicado: (2022)

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
por: Arnhold, Viktor, et al.
Publicado: (2017)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model
por: Ivasko, Sara Marie, et al.
Publicado: (2023)

The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
por: Künkele, Annette, et al.
Publicado: (2013)

Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing
por: Szymansky, Annabell, et al.
Publicado: (2021)

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models
por: Pajtler, Kristian W, et al.
Publicado: (2016)

The Inner and Outer Qualities of Extracellular Vesicles for Translational Purposes in Breast Cancer
por: Schwich, Esther, et al.
Publicado: (2018)

Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion
por: Thorwarth, Anne, et al.
Publicado: (2022)

Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect
por: Arlt, Birte, et al.
Publicado: (2021)

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021)

Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors. An immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors
por: Inaguma, Shingo, et al.
Publicado: (2016)

Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN
por: Fuchs, Steffen, et al.
Publicado: (2023)

Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary
por: Schwich, Esther, et al.
Publicado: (2020)

Increased L1CAM (CD171) levels are associated with glioblastoma and metastatic brain tumors
por: Wachowiak, Robin, et al.
Publicado: (2018)

Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics
por: Lodrini, Marco, et al.
Publicado: (2022)

MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2015)

Detection and Validation of Circular DNA Fragments Using Nanopore Sequencing
por: Tüns, Alicia Isabell, et al.
Publicado: (2022)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

CD14(+)/CD31(+) monocytes expanded by UM171 correct hemophilia A in zebrafish upon lentiviral gene transfer of factor VIII
por: Elnaggar, Muhammad, et al.
Publicado: (2022)

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2016)

Harnessing CD3 diversity to optimize CAR T cells
por: Velasco Cárdenas, Rubí M.-H., et al.
Publicado: (2023)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Effect of HLA-G5 Immune Checkpoint Molecule on the Expression of ILT-2, CD27, and CD38 in Splenic B cells
por: Rohn, Hana, et al.
Publicado: (2022)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

At PS171 (ASTERIX)
Publicado: (1983)

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2017)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma
por: Leipold, Alexander M., et al.
Publicado: (2023)

AB171. Regeneration of rat corpus cavernosa tissue after transplantation of human bone-marrow-derived CD133(+) cells
por: Inoue, Shogo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ap1e6pgs1ln1qcjujmld9lgb25